EASD 2021: Meta-Analysis Demonstrates Sotagliflozin Offers Glycemic and Cardiovascular Benefits in Type 2 Diabetes
Additional long-term and head-to-head studies are needed
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.